Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.
Identifieur interne : 001F44 ( PubMed/Checkpoint ); précédent : 001F43; suivant : 001F45Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.
Auteurs : Javed Ahmad [Inde] ; Sohail Akhter [France] ; Nigel H. Greig [États-Unis] ; Mohammad Amjad Kamal [Arabie saoudite] ; Patrick Midoux [France] ; Chantal Pichon [France]Source :
- Current pharmaceutical design [ 1873-4286 ] ; 2016.
Abstract
Cancer is a highly heterogeneous disease at intra/inter patient levels and known as the leading cause of death worldwide. A variety of mono and combinational therapies including chemotherapy have been evolved over the years for its effective treatment. However, advent of chemotherapeutic resistance or multidrug resistance (MDR) in cancer is a major challenge researchers are facing in cancer chemotherapy. MDR is a complex process having multifaceted non-cellular or cellular-based mechanisms. Research in the area of cancer nanotechnology over the past two decade has now proven that the smartly designed nanoparticles help in successful chemotherapy by overcoming the MDR and preferentially accumulate in the tumor region by means of active and passive targeting therefore reducing the offtarget accumulation of payload. Many of such nanoparticles are in different stages of clinical trials as nanomedicines showing promising result in cancer therapy including the resistant cases. Nanoparticles as chemotherapeutics carriers offer the opportunity to have multiple payload of drug and or imaging agents for combinational and theranostics therapy. Moreover, nanotechnology further bring in notice the new treatment strategies such as combining the NIR, MRI and HIFU in cancer chemotherapy and imaging. Here, we discussed the cellular/non-cellular factors constituting the MDR in cancer and the role of nanomedicines in effective chemotherapy of MDR cases of cancers. Moreover, recent advancements like combinational payload delivery and combined physical approach with nanotechnology in cancer therapy have also been discussed.
PubMed: 27319945
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:27319945Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.</title><author><name sortKey="Ahmad, Javed" sort="Ahmad, Javed" uniqKey="Ahmad J" first="Javed" last="Ahmad">Javed Ahmad</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, UP-229010, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, UP-229010</wicri:regionArea><wicri:noRegion>UP-229010</wicri:noRegion></affiliation></author><author><name sortKey="Akhter, Sohail" sort="Akhter, Sohail" uniqKey="Akhter S" first="Sohail" last="Akhter">Sohail Akhter</name><affiliation wicri:level="1"><nlm:affiliation>LE STUDIUM Loire Valley Institute for Advanced Studies, Centre-Val de Loire region, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>LE STUDIUM Loire Valley Institute for Advanced Studies, Centre-Val de Loire region</wicri:regionArea><wicri:noRegion>Centre-Val de Loire region</wicri:noRegion><wicri:noRegion>Centre-Val de Loire region</wicri:noRegion></affiliation></author><author><name sortKey="Greig, Nigel H" sort="Greig, Nigel H" uniqKey="Greig N" first="Nigel H" last="Greig">Nigel H. Greig</name><affiliation wicri:level="2"><nlm:affiliation>Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National, Institute on Aging, National Institutes of Health, Biomedical Research Center, 251 Bayview Boulevard, Baltimore, MD 21224, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National, Institute on Aging, National Institutes of Health, Biomedical Research Center, 251 Bayview Boulevard, Baltimore, MD 21224</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Kamal, Mohammad Amjad" sort="Kamal, Mohammad Amjad" uniqKey="Kamal M" first="Mohammad Amjad" last="Kamal">Mohammad Amjad Kamal</name><affiliation wicri:level="1"><nlm:affiliation>Metabolomics & Enzymology Unit, Fundamental and Applied Biology Group, King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Metabolomics & Enzymology Unit, Fundamental and Applied Biology Group, King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589</wicri:regionArea><wicri:noRegion>Jeddah 21589</wicri:noRegion></affiliation></author><author><name sortKey="Midoux, Patrick" sort="Midoux, Patrick" uniqKey="Midoux P" first="Patrick" last="Midoux">Patrick Midoux</name><affiliation wicri:level="3"><nlm:affiliation>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation></author><author><name sortKey="Pichon, Chantal" sort="Pichon, Chantal" uniqKey="Pichon C" first="Chantal" last="Pichon">Chantal Pichon</name><affiliation wicri:level="3"><nlm:affiliation>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27319945</idno><idno type="pmid">27319945</idno><idno type="wicri:Area/PubMed/Corpus">002456</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002456</idno><idno type="wicri:Area/PubMed/Curation">002409</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002409</idno><idno type="wicri:Area/PubMed/Checkpoint">002409</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002409</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.</title><author><name sortKey="Ahmad, Javed" sort="Ahmad, Javed" uniqKey="Ahmad J" first="Javed" last="Ahmad">Javed Ahmad</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, UP-229010, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, UP-229010</wicri:regionArea><wicri:noRegion>UP-229010</wicri:noRegion></affiliation></author><author><name sortKey="Akhter, Sohail" sort="Akhter, Sohail" uniqKey="Akhter S" first="Sohail" last="Akhter">Sohail Akhter</name><affiliation wicri:level="1"><nlm:affiliation>LE STUDIUM Loire Valley Institute for Advanced Studies, Centre-Val de Loire region, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>LE STUDIUM Loire Valley Institute for Advanced Studies, Centre-Val de Loire region</wicri:regionArea><wicri:noRegion>Centre-Val de Loire region</wicri:noRegion><wicri:noRegion>Centre-Val de Loire region</wicri:noRegion></affiliation></author><author><name sortKey="Greig, Nigel H" sort="Greig, Nigel H" uniqKey="Greig N" first="Nigel H" last="Greig">Nigel H. Greig</name><affiliation wicri:level="2"><nlm:affiliation>Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National, Institute on Aging, National Institutes of Health, Biomedical Research Center, 251 Bayview Boulevard, Baltimore, MD 21224, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National, Institute on Aging, National Institutes of Health, Biomedical Research Center, 251 Bayview Boulevard, Baltimore, MD 21224</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Kamal, Mohammad Amjad" sort="Kamal, Mohammad Amjad" uniqKey="Kamal M" first="Mohammad Amjad" last="Kamal">Mohammad Amjad Kamal</name><affiliation wicri:level="1"><nlm:affiliation>Metabolomics & Enzymology Unit, Fundamental and Applied Biology Group, King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Metabolomics & Enzymology Unit, Fundamental and Applied Biology Group, King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589</wicri:regionArea><wicri:noRegion>Jeddah 21589</wicri:noRegion></affiliation></author><author><name sortKey="Midoux, Patrick" sort="Midoux, Patrick" uniqKey="Midoux P" first="Patrick" last="Midoux">Patrick Midoux</name><affiliation wicri:level="3"><nlm:affiliation>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation></author><author><name sortKey="Pichon, Chantal" sort="Pichon, Chantal" uniqKey="Pichon C" first="Chantal" last="Pichon">Chantal Pichon</name><affiliation wicri:level="3"><nlm:affiliation>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation></author></analytic><series><title level="j">Current pharmaceutical design</title><idno type="eISSN">1873-4286</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cancer is a highly heterogeneous disease at intra/inter patient levels and known as the leading cause of death worldwide. A variety of mono and combinational therapies including chemotherapy have been evolved over the years for its effective treatment. However, advent of chemotherapeutic resistance or multidrug resistance (MDR) in cancer is a major challenge researchers are facing in cancer chemotherapy. MDR is a complex process having multifaceted non-cellular or cellular-based mechanisms. Research in the area of cancer nanotechnology over the past two decade has now proven that the smartly designed nanoparticles help in successful chemotherapy by overcoming the MDR and preferentially accumulate in the tumor region by means of active and passive targeting therefore reducing the offtarget accumulation of payload. Many of such nanoparticles are in different stages of clinical trials as nanomedicines showing promising result in cancer therapy including the resistant cases. Nanoparticles as chemotherapeutics carriers offer the opportunity to have multiple payload of drug and or imaging agents for combinational and theranostics therapy. Moreover, nanotechnology further bring in notice the new treatment strategies such as combining the NIR, MRI and HIFU in cancer chemotherapy and imaging. Here, we discussed the cellular/non-cellular factors constituting the MDR in cancer and the role of nanomedicines in effective chemotherapy of MDR cases of cancers. Moreover, recent advancements like combinational payload delivery and combined physical approach with nanotechnology in cancer therapy have also been discussed.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27319945</PMID><DateCreated><Year>2016</Year><Month>09</Month><Day>22</Day></DateCreated><DateRevised><Year>2017</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-4286</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>28</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>Current pharmaceutical design</Title><ISOAbbreviation>Curr. Pharm. Des.</ISOAbbreviation></Journal><ArticleTitle>Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.</ArticleTitle><Pagination><MedlinePgn>4360-4373</MedlinePgn></Pagination><Abstract><AbstractText>Cancer is a highly heterogeneous disease at intra/inter patient levels and known as the leading cause of death worldwide. A variety of mono and combinational therapies including chemotherapy have been evolved over the years for its effective treatment. However, advent of chemotherapeutic resistance or multidrug resistance (MDR) in cancer is a major challenge researchers are facing in cancer chemotherapy. MDR is a complex process having multifaceted non-cellular or cellular-based mechanisms. Research in the area of cancer nanotechnology over the past two decade has now proven that the smartly designed nanoparticles help in successful chemotherapy by overcoming the MDR and preferentially accumulate in the tumor region by means of active and passive targeting therefore reducing the offtarget accumulation of payload. Many of such nanoparticles are in different stages of clinical trials as nanomedicines showing promising result in cancer therapy including the resistant cases. Nanoparticles as chemotherapeutics carriers offer the opportunity to have multiple payload of drug and or imaging agents for combinational and theranostics therapy. Moreover, nanotechnology further bring in notice the new treatment strategies such as combining the NIR, MRI and HIFU in cancer chemotherapy and imaging. Here, we discussed the cellular/non-cellular factors constituting the MDR in cancer and the role of nanomedicines in effective chemotherapy of MDR cases of cancers. Moreover, recent advancements like combinational payload delivery and combined physical approach with nanotechnology in cancer therapy have also been discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ahmad</LastName><ForeName>Javed</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, UP-229010, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Akhter</LastName><ForeName>Sohail</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>LE STUDIUM Loire Valley Institute for Advanced Studies, Centre-Val de Loire region, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greig</LastName><ForeName>Nigel H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National, Institute on Aging, National Institutes of Health, Biomedical Research Center, 251 Bayview Boulevard, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamal</LastName><ForeName>Mohammad Amjad</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Metabolomics & Enzymology Unit, Fundamental and Applied Biology Group, King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Enzymoics, 7 Peterlee Place, Hebersham, NSW 2770, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Midoux</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pichon</LastName><ForeName>Chantal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Nucleic acids transfer by non-viral methods, Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZIA AG000311-16</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Curr Pharm Des</MedlineTA><NlmUniqueID>9602487</NlmUniqueID><ISSNLinking>1381-6128</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Cancer Lett. 2006 May 18;236(2):302-8</RefSource><PMID Version="1">15990222</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharm Sci. 2009 Jun 28;37(3-4):508-13</RefSource><PMID Version="1">19406231</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharm Res. 2007 Dec;24(12):2402-11</RefSource><PMID Version="1">17828616</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nanomedicine (Lond). 2010 Jun;5(4):597-615</RefSource><PMID Version="1">20528455</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Pharm. 2009 Sep-Oct;6(5):1353-62</RefSource><PMID Version="1">19507896</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2006 Dec 1;116(3):275-84</RefSource><PMID Version="1">17097178</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Lett. 2013 Jul 1;334(2):263-73</RefSource><PMID Version="1">22902994</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Drug Discov. 2008 Sep;7(9):771-82</RefSource><PMID Version="1">18758474</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Resist Updat. 2012 Feb-Apr;15(1-2):21-38</RefSource><PMID Version="1">22356866</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Metastasis Rev. 2007 Jun;26(2):225-39</RefSource><PMID Version="1">17440684</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2010 Apr 15;464(7291):1067-70</RefSource><PMID Version="1">20305636</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Clin Invest. 2006 Jun;36(6):409-18</RefSource><PMID Version="1">16684125</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2007 Apr 23;118(3):275-84</RefSource><PMID Version="1">17300849</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Biosyst. 2011 May;7(5):1512-22</RefSource><PMID Version="1">21350763</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2001 Jan;7(1):202-9</RefSource><PMID Version="1">11205910</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Crit Rev Ther Drug Carrier Syst. 2012;29(5):355-419</RefSource><PMID Version="1">22876808</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Urol Oncol. 2008 Jan-Feb;26(1):74-85</RefSource><PMID Version="1">18190835</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomaterials. 2010 Mar;31(8):2371-9</RefSource><PMID Version="1">20031202</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Resist Updat. 2011 Jun;14(3):150-63</RefSource><PMID Version="1">21330184</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomaterials. 2012 Jun;33(17):4424-30</RefSource><PMID Version="1">22425551</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomed Res Int. 2014;2014:984756</RefSource><PMID Version="1">25114933</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biotechnol Adv. 2013 Dec;31(8):1397-407</RefSource><PMID Version="1">23800690</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2013 Apr;49(6):1297-304</RefSource><PMID Version="1">23290787</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2004 Jun;4(6):437-47</RefSource><PMID Version="1">15170446</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Pharmacol Sci. 1988 Jun;9(6):190-3</RefSource><PMID Version="1">3073552</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Small. 2009 Dec;5(23):2673-7</RefSource><PMID Version="1">19780069</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cancer Ther. 2009 Aug;8(8):2266-75</RefSource><PMID Version="1">19671743</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2010 Jan;119(2):255-69</RefSource><PMID Version="1">19221875</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2001 Nov 2;85(9):1359-67</RefSource><PMID Version="1">11720475</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Chemother Pharmacol. 2006 Dec;58(6):776-84</RefSource><PMID Version="1">16532342</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2004 Oct;4(10):806-13</RefSource><PMID Version="1">15510161</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Drug Metab. 2009 Oct;10(8):836-41</RefSource><PMID Version="1">20214578</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomaterials. 2011 Apr;32(11):2894-906</RefSource><PMID Version="1">21256584</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2000 Oct 15;60(20):5761-6</RefSource><PMID Version="1">11059771</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomaterials. 2010 Jun;31(18):4995-5006</RefSource><PMID Version="1">20347138</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Pharm. 2011 Dec 5;8(6):2032-8</RefSource><PMID Version="1">21981633</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncogene. 2012 May 10;31(19):2412-22</RefSource><PMID Version="1">21996734</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Drug Deliv Rev. 2012 Jun 15;64(9):826-35</RefSource><PMID Version="1">22465784</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nanomedicine. 2010 Apr;6(2):210-3</RefSource><PMID Version="1">20060074</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cancer Ther. 2011 May;10(5):761-9</RefSource><PMID Version="1">21411714</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2000 Oct 3;69(1):43-52</RefSource><PMID Version="1">11018545</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Pharm. 2011 Sep 15;416(1):296-9</RefSource><PMID Version="1">21703341</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nanomedicine. 2012 Feb;8(2):204-11</RefSource><PMID Version="1">21704592</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Med. 2002;53:615-27</RefSource><PMID Version="1">11818492</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Med Res Rev. 2012 Nov;32(6):1220-62</RefSource><PMID Version="1">21374643</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncol Lett. 2014 Feb;7(2):387-392</RefSource><PMID Version="1">24396453</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Angew Chem Int Ed Engl. 2009;48(30):5418-29</RefSource><PMID Version="1">19562807</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Chemother Pharmacol. 2009 Mar;63(4):711-22</RefSource><PMID Version="1">18618115</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Biotechnol. 2012 Jul 10;30(7):679-92</RefSource><PMID Version="1">22781697</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Pharm. 2004 Jul-Aug;1(4):317-30</RefSource><PMID Version="1">15981591</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2000 Feb 14;64(1-3):143-53</RefSource><PMID Version="1">10640653</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Discov Today. 2007 Jan;12(1-2):34-42</RefSource><PMID Version="1">17198971</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 1992 Nov 15;52(22):6371-4</RefSource><PMID Version="1">1423283</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharm Biopharm. 2010 Mar;74(3):467-73</RefSource><PMID Version="1">20064608</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Methods Mol Biol. 2010;596:1-14</RefSource><PMID Version="1">19949917</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nanomedicine (Lond). 2010 Feb;5(2):193-208</RefSource><PMID Version="1">20148632</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 1972 Aug;26(4):239-57</RefSource><PMID Version="1">4561027</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2000 Jan 7;100(1):57-70</RefSource><PMID Version="1">10647931</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Langmuir. 2008 Jan 15;24(2):568-74</RefSource><PMID Version="1">18052300</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>ACS Nano. 2011 May 24;5(5):3679-92</RefSource><PMID Version="1">21462992</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Pharm. 2011 Jun 6;8(3):852-66</RefSource><PMID Version="1">21480667</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Drug Deliv Rev. 2013 Nov;65(13-14):1866-79</RefSource><PMID Version="1">24120656</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Pharm. 2009 May-Jun;6(3):928-39</RefSource><PMID Version="1">19278222</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Chem Commun (Camb). 2012 Apr 25;48(33):3911-26</RefSource><PMID Version="1">22428156</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2012 Jul 10;161(1):50-61</RefSource><PMID Version="1">22562066</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Treat Rev. 2008 Nov;34(7):592-602</RefSource><PMID Version="1">18538481</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biomater Sci Polym Ed. 2010;21(3):303-14</RefSource><PMID Version="1">20178687</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 1994 Jan 15;54(2):357-61</RefSource><PMID Version="1">8275468</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Pharm. 2006 Mar-Apr;3(2):113-23</RefSource><PMID Version="1">16579640</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>IEEE Trans Nanobioscience. 2005 Jun;4(2):180-95</RefSource><PMID Version="1">16117026</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Huazhong Univ Sci Technolog Med Sci. 2009 Apr;29(2):239-42</RefSource><PMID Version="1">19399413</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Opin Drug Deliv. 2012 Oct;9(10):1225-43</RefSource><PMID Version="1">22897613</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharm Biopharm. 2008 Nov;70(3):718-25</RefSource><PMID Version="1">18647651</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pharm Sci. 2010 Dec;99(12 ):4874-9</RefSource><PMID Version="1">20821385</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2009 Aug 19;138(1):45-8</RefSource><PMID Version="1">19389432</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Drug Deliv. 2013;2013:705265</RefSource><PMID Version="1">23533772</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Hyperthermia. 1995 Mar-Apr;11(2):211-6</RefSource><PMID Version="1">7790735</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomaterials. 2013 Jul;34(21):5344-58</RefSource><PMID Version="1">23591391</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharm Biopharm. 2013 May;84(1):1-20</RefSource><PMID Version="1">23313176</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Drug Deliv Rev. 2013 Jan;65(1):36-48</RefSource><PMID Version="1">23036225</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Drug Metab. 2015;16(8):633-44</RefSource><PMID Version="1">26264206</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Methods Mol Biol. 2010;596:467-88</RefSource><PMID Version="1">19949937</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nanomedicine. 2011 Jun;7(3):324-32</RefSource><PMID Version="1">21094277</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pigment Cell Melanoma Res. 2009 Aug;22(4):388-99</RefSource><PMID Version="1">19493316</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Liposome Res. 2005;15(3-4):141-55</RefSource><PMID Version="1">16393906</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2010 Dec 15;16(24):6139-49</RefSource><PMID Version="1">20876255</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2007 Oct 15;121(8):1830-8</RefSource><PMID Version="1">17557285</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2000 Mar 1;60(5):1197-201</RefSource><PMID Version="1">10728674</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nanomedicine (Lond). 2012 Oct;7(10):1577-90</RefSource><PMID Version="1">23148540</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2009 Jan;9(1):28-39</RefSource><PMID Version="1">19104514</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Mol Life Sci. 2008 Oct;65(20):3145-67</RefSource><PMID Version="1">18581055</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2012 Aug 20;162(1):45-55</RefSource><PMID Version="1">22698943</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2009 May 12;106(19):7957-61</RefSource><PMID Version="1">19383798</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2007 May 15;67(10):4843-50</RefSource><PMID Version="1">17510414</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2001 Feb;86(2):121-7</RefSource><PMID Version="1">11224479</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer J. 2012 Mar-Apr;18(2):124-31</RefSource><PMID Version="1">22453012</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2002 Oct 4;83(2):303-5</RefSource><PMID Version="1">12363455</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Discov Today. 2012 Sep;17(17-18):1044-52</RefSource><PMID Version="1">22652342</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 2011 Jun;1807(6):735-45</RefSource><PMID Version="1">21453675</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2003 Jul 4;21(23):3319-29</RefSource><PMID Version="1">12804863</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pharm Sci. 2002 Jan;91(1):157-70</RefSource><PMID Version="1">11782905</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54</RefSource><PMID Version="1">17895480</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nanoscale. 2011 Oct 5;3(10):4314-22</RefSource><PMID Version="1">21892492</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Cancer. 2009 Nov 16;9:399</RefSource><PMID Version="1">19917123</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2008 Sep 15;68(18):7638-49</RefSource><PMID Version="1">18794153</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Pharm. 2012 Jan 17;422(1-2):229-37</RefSource><PMID Version="1">22093954</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Drug Deliv Rev. 2013 Nov;65(13-14):1699-715</RefSource><PMID Version="1">23611952</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Drug Deliv Rev. 2013 Nov;65(13-14):1748-62</RefSource><PMID Version="1">23973912</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2001 Apr 28;71(3):239-49</RefSource><PMID Version="1">11295217</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>ACS Nano. 2011 Jun 28;5(6):5202-13</RefSource><PMID Version="1">21627074</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Pharm. 2007 Sep-Oct;4(5):713-22</RefSource><PMID Version="1">17708653</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomaterials. 2014 Jan;35(4):1240-8</RefSource><PMID Version="1">24239110</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2008 Dec 18;132(3):164-70</RefSource><PMID Version="1">18571265</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2008 Sep;8(9):705-13</RefSource><PMID Version="1">19143055</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Drug Metab. 2009 Oct;10(8):861-74</RefSource><PMID Version="1">20214582</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biomed Mater Res A. 2008 Jul;86(1):48-60</RefSource><PMID Version="1">17941015</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>ACS Nano. 2014 Mar 25;8(3):2183-95</RefSource><PMID Version="1">24494862</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Surg Oncol. 2012 Sep;21(3):172-7</RefSource><PMID Version="1">21963199</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomaterials. 2012 Oct;33(29):7103-14</RefSource><PMID Version="1">22796159</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Pharm. 2007 Feb 1;329(1-2):94-102</RefSource><PMID Version="1">16997518</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Discov Today. 2013 Dec;18(23-24):1292-300</RefSource><PMID Version="1">24055842</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Chem Soc. 2008 Aug 13;130(32):10643-7</RefSource><PMID Version="1">18642918</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16649-54</RefSource><PMID Version="1">17075050</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomaterials. 2013 May;34(14):3626-38</RefSource><PMID Version="1">23422592</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEMS Microbiol Rev. 1998 Apr;22(1):1-20</RefSource><PMID Version="1">9640644</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pharm Sci. 2014 May;103(5):1538-47</RefSource><PMID Version="1">24619562</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ther Deliv. 2010 Aug;1(2):257-72</RefSource><PMID Version="1">22816132</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2011 Jun;11(6):393-410</RefSource><PMID Version="1">21606941</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Fundam Clin Pharmacol. 2008 Aug;22(4):429-37</RefSource><PMID Version="1">18705753</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2006 May 30;112(3):312-9</RefSource><PMID Version="1">16626835</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomaterials. 2012 Feb;33(6):1808-20</RefSource><PMID Version="1">22136714</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2006 May 30;103(22):8469-74</RefSource><PMID Version="1">16709667</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Cancer Res. 2005;94:143-96</RefSource><PMID Version="1">16096001</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2005 Mar 21;103(2):405-18</RefSource><PMID Version="1">15763623</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharm Res. 2011 Dec;28(12):3069-78</RefSource><PMID Version="1">21879387</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Pharm. 2014 Mar 3;11(3):885-94</RefSource><PMID Version="1">24483832</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Death Differ. 2000 Jul;7(7):682-3</RefSource><PMID Version="1">11023343</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomaterials. 2010 May;31(13):3694-706</RefSource><PMID Version="1">20144478</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2002 Sep 1;62(17 ):5035-40</RefSource><PMID Version="1">12208758</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Drug Deliv Rev. 2008 Jun 30;60(10):1153-66</RefSource><PMID Version="1">18486268</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Pharm. 2002 Mar 2;234(1-2):129-38</RefSource><PMID Version="1">11839444</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acc Chem Res. 2011 Oct 18;44(10):1009-17</RefSource><PMID Version="1">21761902</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nano Lett. 2010 Sep 8;10(9):3223-30</RefSource><PMID Version="1">20726522</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90</RefSource><PMID Version="1">21296855</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nanotechnol Sci Appl. 2015 Nov 19;8:55-66</RefSource><PMID Version="1">26640374</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2009 Mar 15;15(6):1973-80</RefSource><PMID Version="1">19276264</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2011 Jun 30;152(3):418-25</RefSource><PMID Version="1">21435362</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharm Res. 2011 Feb;28(2):237-59</RefSource><PMID Version="1">21104301</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2002 May 31;296(5573):1655-7</RefSource><PMID Version="1">12040186</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 2007 Mar;1768(3):678-87</RefSource><PMID Version="1">17208196</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Res Gerontol Nurs. 2008 Apr;1(2):123-33</RefSource><PMID Version="1">20078025</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem Pharmacol. 2012 Apr 15;83(8):1104-11</RefSource><PMID Version="1">22285912</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomaterials. 2010 Feb;31(4):757-68</RefSource><PMID Version="1">19818492</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2006 Aug 28;114(2):153-62</RefSource><PMID Version="1">16889867</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2007 May 1;13(9):2722-7</RefSource><PMID Version="1">17473205</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2012 Jun 10;160(2):281-9</RefSource><PMID Version="1">22019556</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>ACS Nano. 2010 Aug 24;4(8):4539-50</RefSource><PMID Version="1">20731437</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2002 Nov 7;84(1-2):39-47</RefSource><PMID Version="1">12399166</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2012 Jun 07;12 (7):494-501</RefSource><PMID Version="1">22673150</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Physiol Rev. 2011 Jul;91(3):1071-121</RefSource><PMID Version="1">21742796</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Cancer Drug Targets. 2013 May;13(4):362-78</RefSource><PMID Version="1">23517593</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cancer Res. 2006 Feb;4(2):61-70</RefSource><PMID Version="1">16513837</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2006 Sep;6(9):688-701</RefSource><PMID Version="1">16900224</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncotarget. 2012 Jun;3(6):640-50</RefSource><PMID Version="1">22791660</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Drug Deliv Rev. 2013 Nov;65(13-14):1731-47</RefSource><PMID Version="1">24036273</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomaterials. 2011 Oct;32(30):7711-20</RefSource><PMID Version="1">21816467</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>ACS Nano. 2010 Mar 23;4(3):1399-408</RefSource><PMID Version="1">20148593</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Pharm. 2011 Jun 6;8(3):683-700</RefSource><PMID Version="1">21491921</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomaterials. 2009 Apr;30(10):1954-61</RefSource><PMID Version="1">19138797</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Drug Target. 2008 Dec;16(10):758-72</RefSource><PMID Version="1">18985508</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biomed Mater Res A. 2007 Mar 15;80(4):852-60</RefSource><PMID Version="1">17072850</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Cell Biol. 2005 Dec;17(6):631-6</RefSource><PMID Version="1">16226451</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>ACS Nano. 2013 Feb 26;7(2):994-1005</RefSource><PMID Version="1">23289892</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2005 Jan 20;102(1):203-22</RefSource><PMID Version="1">15653146</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2009 Jun 1;15(11):3770-80</RefSource><PMID Version="1">19470734</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharm Res. 2010 Jan;27(1):200-8</RefSource><PMID Version="1">19894105</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2011 Nov 7;155(3):435-41</RefSource><PMID Version="1">21641946</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>ACS Nano. 2012 May 22;6(5):4483-93</RefSource><PMID Version="1">22540892</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>04</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>07</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27319945</ArticleId><ArticleId IdType="pmc">PMC5182049</ArticleId><ArticleId IdType="mid">NIHMS837362</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Arabie saoudite</li><li>France</li><li>Inde</li><li>États-Unis</li></country><region><li>Centre-Val de Loire</li><li>Maryland</li><li>Région Centre</li></region><settlement><li>Orléans</li></settlement></list><tree><country name="Inde"><noRegion><name sortKey="Ahmad, Javed" sort="Ahmad, Javed" uniqKey="Ahmad J" first="Javed" last="Ahmad">Javed Ahmad</name></noRegion></country><country name="France"><noRegion><name sortKey="Akhter, Sohail" sort="Akhter, Sohail" uniqKey="Akhter S" first="Sohail" last="Akhter">Sohail Akhter</name></noRegion><name sortKey="Midoux, Patrick" sort="Midoux, Patrick" uniqKey="Midoux P" first="Patrick" last="Midoux">Patrick Midoux</name><name sortKey="Pichon, Chantal" sort="Pichon, Chantal" uniqKey="Pichon C" first="Chantal" last="Pichon">Chantal Pichon</name></country><country name="États-Unis"><region name="Maryland"><name sortKey="Greig, Nigel H" sort="Greig, Nigel H" uniqKey="Greig N" first="Nigel H" last="Greig">Nigel H. Greig</name></region></country><country name="Arabie saoudite"><noRegion><name sortKey="Kamal, Mohammad Amjad" sort="Kamal, Mohammad Amjad" uniqKey="Kamal M" first="Mohammad Amjad" last="Kamal">Mohammad Amjad Kamal</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F44 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001F44 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:27319945
|texte= Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:27319945" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |